

## **REMARKS**

### **I. Status of Claims**

Claims 1-3 and 5-6 have been canceled without prejudice in response to the Restriction Requirement. Claims 4 and 7-9 are now pending. It is respectfully submitted that no new matter was added in this amendment.

### **II. Restriction Requirement**

In the Office Action, the Examiner asserted that the present application contains claims which are directed to the following two distinct inventions and stated that restriction to one of the two inventions is required:

- I. Claims 1-3 and 5-6, directed to a prophylactic or therapeutic for diabetes mellitus, which comprises a growth hormone secretagogue receptor (GHS-R) antagonist as an active agent drawn to a dosing device; and
- II. Claims 4 and 7-9, directed to a method of administering an effective dose of a GHS-R antagonist.

In response, Applicants elect, without traverse, Group II (claims 4 and 7-9), directed to a method of administering an effective dose of a GHS-R antagonist.

Conclusion

An early and favorable action on the merits is earnestly requested. A request for a one-month extension of time to reply to the Office Action along with the requisite fee is enclosed.

Respectfully submitted,  
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: Benjamin S. DiMarco  
Benjamin S. DiMarco,  
Reg. No. 50,129

DAVIDSON, DAVIDSON & KAPPEL, LLC  
485 Seventh Avenue, 14<sup>th</sup> Floor  
New York, New York 10018  
(212) 736-1940